On September 15, the chief shares of Britain remained feeble at noontime, after experiencing significant advances due to strong commodity issues and recovery of banks.

At 1043 GMT, the FTSE 100 index slipped 0.2% or 11.39 points, settling at 5,556.02.

The energy issues also didn’t perform well and crude CLc1 prices dropped. The shares of BP declined 1.5% and performed the worst.

After FDA extended the period to appraise its heart drug Brilinta, AstraZeneca shunned 1.3%. There was a drop of 0.3% in the share prices of GlaxoSmithKline, as analysts degraded its grade from buy to hold.

Talking about the miners, African Barrick Gold decreased 2.4%, thanks to surging metal prices due to increase in Dollar.

No significant slumps were faced by banking sector, as conciliatory efforts by Basel III. Barclays dropped 0.65. Icap, an inter-dealer broker went down 1.9%. The Standard Life performed the best, with its prices moving up 1.9% contributed by its strong equity valuations and takeover.

The gain was experienced by Next, the fashion retailer because of its projection of high profits in the first half, advancing 4.9%. It also provided advantage to other retailers such as Marks & Spencer and Kingfisher, which climbed up 2.0% and 2.45, respectively.

Mic Mills, Head of electronic trading at ETX Capital said, "There is just a little drift back after the good gains seen in the past few weeks, with investors pausing for breath in the absence of much fresh news or data for direction".